Applications of patient-derived tumor xenograft models and tumor organoids
GJ Yoshida - Journal of hematology & oncology, 2020 - Springer
Patient-derived tumor xenografts (PDXs), in which tumor fragments surgically dissected from
cancer patients are directly transplanted into immunodeficient mice, have emerged as a …
cancer patients are directly transplanted into immunodeficient mice, have emerged as a …
[HTML][HTML] Translating complexity and heterogeneity of pancreatic tumor: 3D in vitro to in vivo models
MA Heinrich, AMRH Mostafa, JP Morton… - Advanced drug delivery …, 2021 - Elsevier
Pancreatic ductal adenocarcinoma (PDAC) is an extremely aggressive type of cancer with
an overall survival rate of less than 7-8%, emphasizing the need for novel effective …
an overall survival rate of less than 7-8%, emphasizing the need for novel effective …
Mutant KRAS-driven cancers depend on PTPN11/SHP2 phosphatase
DA Ruess, GJ Heynen, KJ Ciecielski, J Ai… - Nature medicine, 2018 - nature.com
The ubiquitously expressed non-receptor protein tyrosine phosphatase SHP2, encoded by
PTPN11, is involved in signal transduction downstream of multiple growth factor, cytokine …
PTPN11, is involved in signal transduction downstream of multiple growth factor, cytokine …
Inflammatory cytokine–regulated tRNA-derived fragment tRF-21 suppresses pancreatic ductal adenocarcinoma progression
L Pan, X Huang, ZX Liu, Y Ye, R Li… - The Journal of …, 2021 - Am Soc Clin Investig
The tumorigenic mechanism for pancreatic ductal adenocarcinoma (PDAC) is not clear,
although chronic inflammation is implicated. Here, we identified an inflammatory cytokine …
although chronic inflammation is implicated. Here, we identified an inflammatory cytokine …
Syndecan 1 is a critical mediator of macropinocytosis in pancreatic cancer
Pancreatic ductal adenocarcinoma (PDAC) remains recalcitrant to all forms of cancer
treatment and carries a five-year survival rate of only 8%. Inhibition of oncogenic KRAS …
treatment and carries a five-year survival rate of only 8%. Inhibition of oncogenic KRAS …
MYC instructs and maintains pancreatic adenocarcinoma phenotype
The signature features of pancreatic ductal adenocarcinoma (PDAC) are its
fibroinflammatory stroma, poor immune activity, and dismal prognosis. We show that acute …
fibroinflammatory stroma, poor immune activity, and dismal prognosis. We show that acute …
KRAS-related proteins in pancreatic cancer
Pancreatic ductal adenocarcinoma (PDAC) is a highly metastatic disease with a high
mortality rate. Genetic and biochemical studies have shown that RAS signaling mediated by …
mortality rate. Genetic and biochemical studies have shown that RAS signaling mediated by …
Tumor microenvironment remodeling enables bypass of oncogenic KRAS dependency in pancreatic cancer
Oncogenic KRAS (KRAS*) is a key tumor maintenance gene in pancreatic ductal
adenocarcinoma (PDAC), motivating pharmacologic targeting of KRAS* and its effectors …
adenocarcinoma (PDAC), motivating pharmacologic targeting of KRAS* and its effectors …
[HTML][HTML] Overcoming adaptive resistance to KRAS and MEK inhibitors by co-targeting mTORC1/2 complexes in pancreatic cancer
Activating KRAS mutations are found in over 90% of pancreatic ductal adenocarcinomas
(PDACs), yet KRAS has remained a difficult target to inhibit pharmacologically. Here, we …
(PDACs), yet KRAS has remained a difficult target to inhibit pharmacologically. Here, we …
[HTML][HTML] Recent advances in targeted therapy for pancreatic adenocarcinoma
YT Fang, WW Yang, YR Niu, YK Sun - World journal of …, 2023 - ncbi.nlm.nih.gov
Pancreatic adenocarcinoma (PDAC) is a fatal disease with a 5-year survival rate of 8% and
a median survival of 6 mo. In PDAC, several mutations in the genes are involved, with …
a median survival of 6 mo. In PDAC, several mutations in the genes are involved, with …